-
Age associated SARS-CoV-2 immune responses provide insights into population immunity over four years since the COVID-19 pandemic
- Back
Metadata
Document Title
Age associated SARS-CoV-2 immune responses provide insights into population immunity over four years since the COVID-19 pandemic
Name from Authors Collection
Affiliations
Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand; Molecular Biology of Dengue and Flaviviruses Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Development Agency, NSTDA, Pathum Thani, 12120, Thailand; Division of Dengue Hemorrhagic Fever Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand; Siriraj Center of Research Excellence in Dengue and Emerging Pathogens, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand; Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, 10330, Thailand; The Royal Society of Thailand (FRS(T)), Sanam Sueapa, Dusit, Bangkok, 10330, Thailand
Type
Article
Source Title
Scientific Reports
ISSN
20452322
Year
2025
Volume
15
Issue
1
Open Access
All Open Access; Gold Open Access; Green Open Access
Publisher
Nature Research
DOI
10.1038/s41598-025-05737-z
Abstract
As SARS-CoV-2 variants continue to emerge, the extent of their impact on shaping population immunity through repeated waves remains poorly understood. This study assessed age-specific immune responses and the effects of vaccination on neutralization against wild-type (WT) and JN.1 variants. We analyzed 4,371 serum samples from individuals aged 6 months–80 years (May-August 2024). We found that 95.1% of participants had detectable anti-N Ig, suggesting widespread prior infection. Among unvaccinated children (6 months–4 years), 96.5% exhibited anti-RBD or anti-N Ig antibodies mostly from asymptomatic infections. Neutralization against JN.1 did not significantly differ by age, but children aged 6 months–4 years exhibited higher JN.1 neutralization than WT, while individuals aged ≥ 12 years showed the opposite pattern. Unvaccinated individuals demonstrated stronger neutralization against JN.1, whereas vaccinated participants had lower neutralization against JN.1 relative to WT, regardless of vaccine dose. No significant differences in JN.1 neutralization were observed across vaccine doses or age groups. Although 86.5% of participants exhibited neutralizing activity against JN.1, the titers remained relatively low. These findings highlight that almost all children experienced asymptomatic SARS-CoV-2 infection and suggest that natural exposure maintains immunity in adults. Infection-driven boosting may improve community-wide protection and alleviate immune imprinting, offering key insights for optimizing vaccine strategies. © The Author(s) 2025.
Keyword
Antibody | COVID-19 | JN.1 | omicron | SARS-CoV-2 | Seroprevalence
Knowledge Taxonomy Level 1
Knowledge Taxonomy Level 2
Knowledge Taxonomy Level 3
License
CC BY-NC-ND
Rights
Authors
Publication Source
Scopus
Publication Source
Scopus